Biochem/physiol Actions

Reversible: yes

Product does not compete with ATP.

Primary TargetNOS in vitro

Target IC₅₀: 2-3 µM inhibiting nitric oxide synthase in vitro

Cell permeable: yes

General description

A cell-permeable, reversible inhibitor of nitric oxide synthase in vitro (IC₅₀ = 2-3 µM) and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.

Endogenous reversible inhibitor of nitric oxide synthesis in vitro and in vivo. Causes dose-dependent vasoconstriction and bradycardic effects.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Closs, E.I., et al. 1997. Nitric Oxide1, 65.Faraci, F.M., et al. 1995. Am. J. Physiol.269, H1522.Gardiner, S.M., et al. 1993. Br. J. Pharmacol. 110, 1457.Kotani, K., et al. 1992. J. Neurochem.58, 1127.Vallance, P., et al. 1992. Lancet339, 572.

Packaging

Packaged under inert gas

25 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.

Warning

Toxicity: Standard Handling (A)